Treatment News : Encouraging Results for BMS’s Oral HIV Attachment Inhibitor - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 1, 2011

Encouraging Results for BMS’s Oral HIV Attachment Inhibitor

by Tim Horn

Bristol-Myers Squibb reported encouraging preliminary results from a short study evaluating its oral version of a new class of antiretrovirals (ARVs): an attachment inhibitor currently dubbed BMS-663068 (BMS-068). The data were reported Monday, February 28, by Richard Nettles, MD, of BMS at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) at Boston.

Like the approved ARVs Fuzeon (enfuvirtide) and Selzentry (maraviroc), BMS-068 prevents HIV from entering CD4 cells and thus establishing infection. However, it does so in a different manner than these approved agents. Whereas Selzentry blocks the way HIV interacts with the CCR5 receptor on CD4 cells and Fuzeon prevents the fusion of the virus and cell membranes, BMS-068 acts even earlier in the process—it prevents HIV’s gp120 protein from docking with the CD4 cells’ protein.

Most attachment inhibitors studied in clinical trials thus far need to be injected, as the active drugs are very sensitive and do not make it past gastric juices in the stomach and intestine. Researchers at BMS have found a way to administer its attachment inhibitor orally and presented data at CROI from their first study involving HIV-positive patients.

The study enrolled 50 patients into one of five dosing groups. In Group A, patients took 600 milligrams (mg) of BMS-068 plus 100 mg Norvir (ritonavir), twice a day. In Group B, patients took 1,200 mg BMS-068 plus 100 mg Norvir, once a day. In Group C, patients took 1,200 mg BMS-068 plus 100 mg Norvir, twice a day. In Group D, patients took 1,200 BMS-068 twice a day, plus 100 mg Norvir once a day (with the morning dose of BMS-068). Finally, in Group E, the dose was 1,200 mg BMS-068, twice daily, without Norvir.

Average viral load reductions in the patients—all were either new to treatment or off therapy upon entering the study—were pronounced in all groups, ranging from a 1.2 log drop in Group E to a 1.8 log drop in Group C. Maximum viral load reductions ranged from 1.22 log to 1.78 log, which generally occurred several days after the last dose of the drug. 

CD4 increases, ranging from a 23-cell gain in Group E and a 130-cell gain in Group A, were also reported.

BMS-068 was generally well tolerated with no serious adverse events during the brief study. Side effects were generally mild, with rash and headache being the most common.

After conducting an analysis of BMS-068 concentrations in the blood, the researchers concluded that, going forward, the drug can be studied using once- or twice-daily dosing either with or without Norvir. Nettles even suggested that further exploration, at doses lower than those used in this initial Phase IIa study, may be warranted.

On February 16, 2011, the U.S. Food and Drug Administration granted BMS’s request of Fast Track designation for BMS-068, potentially expediting the research and possible approval of the drug. However, additional Phase II and Phase III testing is necessary to prove the drug’s safety and efficacy for the treatment of HIV.

Search: Bristol-Myers Squibb, BMS, attachment inhibitor, BMS-663068, pharmacokinetics


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    RyGuy00
    New York
    New York


    pevans
    San Francisco
    California

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.